Cellectar's 2025 Q2 Earnings Call: Key Contradictions in Phase 3 Trial Strategy and Cost Projections

Regulatory Strategy Shift for Iopofosine I-131:
- Cellectar Biosciences announced a shift in regulatory strategy for iopofosine I-131, planning to pursue an accelerated approval pathway for Waldenstrom's Macroglobulinemia treatment.
- The decision was based on a subset analysis demonstrating iopofosine's potential efficacy in post-BTKi failure patients and having a minimum of 12 months of follow-up data.

Next-Generation Radiopharmaceutical Pipeline Progress:
- Cellectar is advancing CLR 125 and CLR 225 as promising candidates for Phase I trials in triple-negative breast cancer and pancreatic cancer, respectively.
- The progress is supported by strong preclinical results and the submission of Phase I protocols to the FDA.

Financial Position and Fundraising:
- Cellectar reported an ending cash position of $11 million, including $2.3 million raised from a June financing.
- The company has raised nearly $10 million in recent financings to support clinical programs and regulatory milestones.

Operational Strengthening:
- Cellectar secured a long-term isotope supply agreement to support its clinical programs.
- The agreement enhances the company's operational foundation and ensures a stable supply of necessary isotopes for its therapies.